Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Weight loss drugs like Ozempic have gained a lot of popularity However these medications are not without side effects One ...

“The combined impact of these conditions is significant, with reports estimating the cost of excess weight in New Zealand as ...

Associate Health Minister David Seymour says the Government is delivering on its promise to give Kiwis access to more treatments, with Wegovy now ...

At first, Chinese pharmaceutical companies rushed to make similar versions of blockbuster weight-loss drugs, such as Wegovy and Ozempic ... such as sleep apnoea, fatty liver disease, chronic kidney ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Rapid weight loss, especially without strength training, can lead to muscle loss. Therefore, while taking the medicines, ...